•   Australia and New Zealand
  •   Email Us
  •   Australia and New Zealand
  •   Email Us
Alliance Partners
MDSANZ

Give Us A Call

1300 857 230

Method

TO OPERATE OR NOT TO OPERATE?

Artificial hip joints, knee joints, shoulder joints – several hundred thousand of them are implanted in Germany every year, especially in osteoarthritis. The alternative? A molecular orthopaedic method, developed by the globally recognised arthritis specialist Prof. Dr. Wehling from Düsseldorf. The Orthokine® syringe EOT®II is a patented and CE-certified medical device by ORTHOGEN Lab Services GmbH. Your doctor uses this product for the preparation of autologous conditioned serum (ACS), which can be used in the conservative treatment of osteoarthritis. The conservative approach to osteoarthritis strives to avoid surgery wherever possible. Growth factors as well as so-called interleukin antagonists are enriched in the serum by the special processing method. Interleukin antagonists are the endogenous molecular opponents of the interleukin mediators of the cells of the immune system. Interested in more? Prof. Dr. Wehling will personally tell you in the movie.

TARGETED THERAPY OF OSTEOARTHRITIS (AKA. ARTHROSIS)

The principle of action of the Orthokine® therapy offers a targeted treatment that has been documented extensively in scientific studies (see bibliography). The Orthokine® serum obtained using the patented second-generation medical device EOT®II is rich in interleukin-1 receptor antagonists and various growth factors such as Insulin-Like Growth Factor-1, Platelet-Derived Growth Factor and Transforming Growth Factor β-1. In particular, increases in cytokine IL-1 lead to pain symptoms in osteoarthritis. In clinical trials, pain symptoms could be alleviated by the Orthokine® serum.

The Orthokine® serum has been used more than 400,000 times worldwide (internal data, ORTHOGEN AG) and was well-tolerated in all indications. In clinical trials with Orthokine® serum, the rate of adverse events was low.

SCHEMATIC ILLUSTRATION OF THE MODE OF ACTION

SITUATION

The signalling protein interleukin-1 (IL-1) increases in the tissue in case of osteoarthritis (aka. arthrosis) and is responsible for pain and tissue destruction. Cytokines that inhibit IL-1 reduce inflammation, pain and the progression of damage in joints and tissues.

THERAPY

The Orthokine® serum contains elevated levels of anti-inflammatory cytokines and growth factors1, 2. These influence the process leading to inflammation and pain in a biologically active manner.

Effect

The IL-1 receptor antagonist (IL-1Ra) binds to the interleukin-1 receptor and inhibits IL-1. In addition, the growth factors promote regeneration and can delay further degradation of cartilage, as well as concomitantly accelerate the healing of muscle and tendon injuries3, 4, 5.

PATENTED, STANDARDISED METHOD FOR THE PRODUCTION OF ORTHOKINE® SERUM

With the Orthokine® Starter Kit, you have all that you need for the first-hand use of Orthokine® serum in your surgery. As well as the equipment available to be supplied and maintained, our service includes the intensive training of your staff, and various training and information material.

THE 6 STEPS TO THE ORTHOKINE®-SERUM

1. The medical device

2. One-time blood sampling with EOT®II syringes under sterile conditions.

3. Keep the blood at body temperature in the incubator for 6 – 9 hours to stimulate production of ‘good’ endogenous signal proteins.

4. In the centrifuge, separate therapeutically active serum from solid components.

5. After aseptic removal, the Orthokine® serum is ready for use.

6. Always inject serum through a 0.2 µm filter. Shelf life: up to 7 months (at -18 °C / -1 °F or colder)

Quick Enquiry Form